KBP is dedicated to research and development of novel solutions of hypertension, cardiorenal,
and infectious diseases around the world.
Aldosterone is a steroidal hormone that plays a central role in the body’s regulation of blood pressure, sodium and potassium. It does so by acting on mineralocorticoid receptors, regulating reabsorption of sodium and excretion of potassium in the kidney. Dysregulation of aldosterone can contribute to hypertension, and can drive progression of both cardiovascular and kidney disease.
Uncontrolled hypertension in advanced CKD Patients leads to continued renal damage and cardiovascular events.
Existing treatments such as β-blockers, hydralazine, alpha blockers, minoxidil, and current MRAs are all ineffective or contraindicated due to the risk of hyperkalemia and rapidly declining renal function.
Advanced CKD patients with uncontrolled hypertension are most commonly prescribed ACEi/ARBs, CCBs, β-blockers and loop diuretics.
However, each of these drug classes has significant limitations either related to limited effectiveness or safety concerns. MRAs, although known to be effective in the treatment of uncontrolled hypertension, are only prescribed to a small number of advanced CKD patients due to the increased risk of Hyperkalemia.
KBP-5074 is a novel, non-steroidal MRA that selectively binds to the mineralocorticoid receptor with a higher affinity than other drugs in the class. In clinical trials conducted to-date, it has demonstrated an ability to lower blood pressure without androgenic effects such as hirsutism, obesity and gynecomastia.